MAPK3 and endometrial carcinoma: Here, we found that metformin led to a reduction of ERK1/2phosphorylationin endometrial carcinoma cells in a dose-dependent manner, indicating that the ERK1/2 signaling pathway may be involved in the metformin-induced reversal of EMT in endometrial carcinoma cells.